Consensus recommendations on the use of 18F-FDG PET/CT in lung disease




Delphine L. Chen, Safia Ballout, Laigao Chen, Joseph Cheriyan, Gourab Choudhury, Ana M. Denis-Bacelar, Elise Emond, Kjell Erlandsson, Marie Fisk, Francesco Fraioli, Ashley M. Groves, Roger N. Gunn, Jun Hatazawa, Beverly F. Holeman, Brian F. Hutton, Hidehiro Iida, Sarah Lee, William MacNee, Keiko Matsunaga, Divya Mohan, David Parr, Alelah Rashidnasab, Gaia Rizzo, Deepak Subramanian, Ruth Tal-Singer, Kris Thielemans, Nicola Tregay, Edwin J.R. Van Beek, Laurence Vass, Marcos F. Vidal Melo, Jeremy W. Wellen, Ian Wilkinson, Frederick J. Wilson, Tilo Winkler

2020

Journal of Nuclear Medicine

2159-662X

DOIhttps://doi.org/10.2967/jnumed.120.244780

https://jnm.snmjournals.org/content/61/12/1701

https://research.utu.fi/converis/portal/detail/Publication/49142879



Positron emission tomography (PET) with 18F-fluorodeoxyglucose (18F-FDG)
has been increasingly applied, predominantly in the research setting,
to study drug effects and pulmonary biology and
monitor disease progression and treatment outcomes
in lung diseases, disorders that interfere with gas exchange through
alterations
of the pulmonary parenchyma, airways and/or
vasculature. To date, however, there are no widely accepted standard
acquisition
protocols and imaging data analysis methods for
pulmonary 18F-FDG PET/CT in these diseases, resulting in
disparate approaches. Hence, comparison of data across the literature is
challenging.
To help harmonize the acquisition and analysis and
promote reproducibility, acquisition protocol and analysis method
details
were collated from seven PET centers. Based on
this information and discussions among the authors, the consensus
recommendations
reported here on patient preparation, choice of
dynamic versus static imaging, image reconstruction, and image analysis
reporting
were reached.
                 


Last updated on 2024-26-11 at 19:13